1[1]Nugent J, Po AL, Scott EM, et al. Design and delivery of non-parenteral vaccines[J] .J Clin Pharm Ther, 1998, 23(4) :257.
2[2]Chen HM, Recent advances in mucosal vaccine development [J] .J Controlled Release, 2000, 67:117.
3[3]Robert S, Northrup, Anthony S, et al. Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells[J] .J Infect Dis, 1972,125(6) :672.
4[4]Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin [J] .J Immunol,1984, 132:2736.
5[5]Harrod T, Martin M, Russell M W. Long-term persistence and recall of immune response in aged mice after mucosal immunization [J]. Oral Micro biol Immunol, 2001, 16(3): 170.
6[6]Bradney CP, Sempowski GD, Liao HX, et al. Cytocines as aduvants for the induction of anti-immunodeficiency virus peptide immunoglobulin G and IgA antibodies in serum and mucosal secretions after nasal immunization [J]. J Virol, 2002, 76: 517.
7[7]Marinaro M, Staars HF, Hiroi T, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Tb2)cells and IL-4[J] .J Immunol, 1995,155:4621.
8[8]Kim PH, Eckmann L, Lee WJ, et al. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-β1 [J] .J Immunol, 1998,160(3): 1198.
9[9]Okahashi N, Yamamoto M, Vancott JL et al. Oral immunization of interleukin-4 knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD+4 Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses [J], Infect Immun, 1996, 64(5): 1516.
10[10]Douce G, Fontana M, Pizza M et al. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin [J]. Infect Immun, 1997, 65:2821.
2Langford PR, Sansone A, Valenti P, et al. Bacterial superoxide dismutase and virulence [J]. Methods Enzymol. 2002; 349: 155-166.
3Braunstein M, Espinosa BJ, Chan J, et al. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis [J]. Mol Microbiol. 2003; 48(2): 453-464.
4Dunn KL, Farrant JL, Langford PR, et al. Bacterial [Cu,Zn]-cofactored superoxide dismutase protects opsonized, encapsulated Neisseria meningitidis from phagocytosis by human monocytes/macrophages [J]. Infect Immun. 2003; 71(3): 1604-1607.
5Papp-Szabo E, Sutherland CL, Josephy PD. Superoxide dismutase and the resistance of Escherichia coli to phagocytic killing by human neutrophils [J]. Infect Immun. 1993; 61(4): 1442-1446.
6Fang FC, DeGroote MA, Foster JW, et al. Virulent Salmonella typhimurium has two periplasmic Cu, Zn-superoxide dismutases [J]. Proc Natl Acad Sci U S A. 1999; 96(13): 7502-7507.
7Uzzau S, Bossi L, Figueroa-Bossi N. Differential accumulation of Salmonella[Cu, Zn]uperoxide dismutases SodCI and SodCII in intracellular bacteria: correlation with their relative contribution to pathogenicity [J]. Mol Microbiol. 2002; 46(1): 147-156.
8Sly LM, Guiney DG, Reiner NE. Salmonella enterica serovar Typhimurium periplasmic superoxide dismutases SodCI and SodCII are required for protection against the phagocyte oxidative burst [J]. Infect Immun. 2002; 70(9): 5312-5315.
9Farrant JL, Sansone A, Canvin JR, et al. Bacterial copper-and zinc-cofactored superoxide dismutase contributes to the pathogenesis of systemic salmonellosis [J]. Mol Microbiol. 1997; 25(4): 785-796.
10Sansone A, Watson PR, Wallis TS, et al. The role of two periplasmic copper-and zinc-cofactored superoxide dismutases in the virulence of Salmonella choleraesuis [J]. Microbiology. 2002; 148(Pt 3): 719-726.
